Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M510204200 on December 7, 2005

J. Biol. Chem., Vol. 281, Issue 6, 3190-3197, February 10, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/6/3190    most recent
M510204200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chia, D. J.
Right arrow Articles by Rotwein, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chia, D. J.
Right arrow Articles by Rotwein, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Characterization of Distinct Stat5b Binding Sites That Mediate Growth Hormone-stimulated IGF-I Gene Transcription*

Dennis J. Chia{ddagger}, Mitsuru Ono{ddagger}, Joachim Woelfle{ddagger}, Mylynda Schlesinger-Massart{ddagger}, Honglin Jiang§, and Peter Rotwein{ddagger}1

From the {ddagger}Department of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, Oregon 97239 and the §Department of Animal and Poultry Sciences, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061

Received for publication, September 16, 2005


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
A key agent in the anabolic actions of growth hormone (GH) is insulin-like growth factor-I (IGF-I), a 70-amino acid secreted protein with direct effects on somatic growth and tissue maintenance and repair. GH rapidly and potently stimulates IGF-I gene transcription by mechanisms independent of new protein synthesis, and recent studies have linked the transcription factor Stat5b to a regulatory network connecting the activated GH receptor on the cell membrane to the IGF-I gene in the nucleus. Here we analyze two distinct conserved GH response elements in the rat IGF-I locus that contain paired Stat5b sites. Each response element binds Stat5b in vivo in a GH-dependent way, as assessed by chromatin immunoprecipitation assays, and consists of one high affinity and one lower affinity Stat5b site, as determined by both qualitative and quantitative protein-DNA binding studies. In biochemical reconstitution experiments, both response elements are able to mediate GH-stimulated and Stat5b-dependent transcription when fused to a reporter gene containing either the major IGF-I promoter or a minimal neutral promoter, although the paired Stat5b sites located in the second IGF-I intron were more than twice as effective as the response element that mapped ~73 kb 5' to the IGF-I exon 1. Taken together, our results define the initial molecular architecture of a complicated GH-regulated transcriptional pathway, and suggest that apparently redundant hormone response elements provide a mechanism for amplifying GH action at a physiologically important target gene.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The actions of growth hormone (GH)2 on somatic growth and intermediary metabolism have been intertwined with the effects of insulin-like growth factor-I (IGF-I) ever since the somatomedin hypothesis was first proposed nearly 50 years ago (1). Much is now known about the physiology, biochemistry, and signal transduction pathways of both proteins (2, 3), and their interdependent roles in regulating growth during childhood, stimulating tissue regeneration in the adult, and maintaining tissue integrity during aging have been both confirmed and refined in intervening years (4–6).

GH initiates its physiological effects after binding to its membrane-bound receptor, leading to activation of Jak2, a receptor-associated intracellular tyrosine-protein kinase (2), and setting into motion a series of protein phosphorylation steps that stimulate the activity of several transcription factors, including Stats1, 3, 5a, and 5b, among others (7, 8). It has been known for over a dozen years that GH potently induces IGF-I gene transcription (9), causing the sustained accumulation of IGF-I mRNAs and protein (9, 10), yet the signaling pathways connecting the GH receptor and cytoplasmic Jak2 to the nuclear IGF-I gene have been elucidated only recently (2, 11). Contributing to this challenge is the fact that the IGF-I gene is more complicated than would have been predicted from its simple protein sequence. In mammals, the gene is transcribed from tandem promoters, each with distinct leader exons, and its initial transcripts undergo both differential RNA splicing and alternative polyadenylation to yield multiple mature mRNA species encoding distinct IGF-I precursor proteins that are secreted and processed into a single mature bioactive 70-residue IGF-I (12).

Studies from our laboratory have implicated the transcription factor Stat5b as a key component in acute GH-stimulated IGF-I gene activation in rats (11), thus extending previous observations pointing to effects of Stat5b and to a lesser extent Stat5a on regulating postnatal somatic growth in mice (13, 14). More recently, a key role for Stat5b in normal growth in humans was inferred through identification of an individual with a homozygous point mutation in the Stat5b gene, profound short stature, absent clinical responses to exogenous GH, and diminished expression of IGF-I (15). At the same time we reported the characterization of a putative GH response element in the second intron of the rat IGF-I gene, termed HS7, that contains tandem Stat5 binding sites and functions as a cis-regulatory region capable of mediating GH-induced and Stat5b-mediated IGF-I gene transcription (16). Here we use a combination of in vivo analyses in GH-deficient rats, biochemical reconstitution experiments in tissue culture cells, and protein-DNA binding studies in vitro to evaluate a second potential GH response element in the IGF-I locus. We show that this DNA segment also binds Stat5b in a GH-dependent way, and can mediate GH-activated IGF-I gene transcription. Our observations begin to elucidate the molecular architecture of a complex transcriptional pathway and suggest that redundant hormone response elements provide a mechanism for sustaining and amplifying GH action at a physiologically critical target gene.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Antibodies to Stat5 (C17X) were from Santa Cruz Biotechnology (Santa Cruz, CA), anti-FLAG (M2) was from Sigma, and anti-T7 from Novagen (San Diego, CA). Recombinant rat GH was purchased from the National Hormone and Pituitary Program, NIDDK, National Institutes of Health. Oligonucleotides were synthesized at the OHSU Core Facility in the Department of Molecular Microbiology and Immunology. Transit-LT1 was from Mirus (Madison, WI), the Qia-Quick PCR DNA purification kit was from Qiagen (Valencia, CA), and protein A-agarose beads were from Sigma. All other chemicals were reagent grade and were purchased from commercial suppliers.

Recombinant Plasmids—An expression plasmid for the mouse GH receptor in pcDNA3 has been described previously, as have expression plasmids for wild-type and constitutively active rat Stat5b (Stat5bCA, N642H), each modified with an N-terminal FLAG epitope tag (11). Luciferase reporter gene plasmids containing the HS7 region of rat IGF-I intron 2 fused to the TK promoter or to rat IGF-I promoter 1 also have been described (16). A 352-bp fragment of rat genomic DNA located ~73 kb 5' to IGF-I exon 1 was added 5' to each promoter by standard molecular cloning methods. Point mutations were introduced into this plasmid using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Each mutation was verified by DNA sequencing.

Cell Culture, Transient Transfections, and Reporter Gene Assays—COS-7 cells (ATCC CRL-1651) were incubated in antibiotic-free Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and were co-transfected with expression plasmids for the mouse GH receptor and wild-type or constitutively active rat Stat5b, using Transit-LT1 and a protocol from the supplier. After incubation for 24 h, serum-free medium was added containing 1% bovine serum albumin for 4 h, followed by addition of recombinant rat GH (40 nM final concentration) or vehicle for 60 min. Cells were then harvested, and nuclear proteins isolated (17). For reporter gene assays, cells on 6-well tissue culture dishes were co-transfected with mouse GH receptor (100 ng) and wild-type Stat5b (100 ng), and the promoter-reporter plasmids indicated in Figs. 3 and 4 (250 ng). Cells were incubated for 24 h, followed by addition of serum-free medium containing 1% bovine serum albumin and either vehicle or rat GH for 18 h. Cells were then harvested and lysates used for luciferase assays. All results were normalized for total cellular protein concentrations.

Animal Studies—Male Sprague-Dawley rats, hypophysectomized by a transauricular route at age 7 weeks, were purchased from Harlan Sprague-Dawley (Indianapolis, IN). Animals were housed at the OHSU Animal Care Facility on a 12-h light/dark schedule with free access to food and water, and received care according to National Institutes of Health guidelines. Replacement doses of glucocorticoids (cortisol phosphate, 400 µg/kg/d) and thyroxine (10 µg/kg/d) were given daily by subcutaneous injection, and GH deficiency was confirmed by failure to grow during a 2-week observation period. Following this period, rats were injected intraperitoneally with either vehicle (saline) or 1.5 µg/g of recombinant rat GH. At intervals, rats were anesthetized with pentobarbital (50 mg/kg intraperitoneally), and sacrificed. Liver nuclear proteins were isolated as described (17) and RNA and DNA as outlined below. All procedures were approved by the OHSU Committee on Animal Care and Use.

DNA-Protein Binding Studies—Electrophoretic mobility shift assays were performed as indicated (11, 17), with COS-7 or rat hepatic nuclear proteins and 5'-IRDyeTM700-labeled double-stranded oligonucleotides from rat HS7 GHRE-1 (top strand, 5'-GGGCCTTCCTGGAAGAAA-3'); HS7 GHRE-2 (top strand, 5'-CTGTCTGCTTCTTAGAATGAAGAG-3'); 5' distal region RE-1 (top strand, 5'-AGTCAGGAAAATTCTAAGAAACTGCCTCCAG-3'); 5' distal region RE-2 (top strand, 5'-GCCTTTTTTTTTTCTTAGAAGTAAGGGTAAA-3'); or with a binding site for Sp1 (top strand, 5'-ATTCGATCGGGGCGGGGCGAGC-3'). After incubation of proteins and DNA for 30 min at 4 °C, products were separated by electrophoresis through non-denaturing 4 or 5% polyacrylamide gels in 1x Tris borate/EDTA (90 mM Tris, 90 mM boric acid, and 2 mM EDTA, pH 8.3) at 200 V for 25–35 min at 20 °C. Results were analyzed using an Odyssey infrared imaging system and v1.2 analysis software (LiCoR Biosciences, Lincoln, NB). Antibody supershift and competition experiments were as described (17). The top strand of the nonspecific competitor oligonucleotide is as follows: Oct-1: 5'-TTTTAGAGGATCCATGCAAATGGACGTACG-3'.

Quantitative DNA-protein binding studies were performed with a constant amount of protein (2.8 µg of COS-7 cell nuclear extract) and increasing concentrations of 5'-IRDyeTM700-labeled probes (0.5–25 nM). After electrophoresis, gels were dried, and the bands representing protein-bound DNA and free probe measured using a LiCoR Odyssey infrared scanner and v1.2 analysis software. The dissociation constants (Kd) were calculated from these data as the negative reciprocal of the slope after results were graphed by Scatchard plot analysis.

RNA Analysis—Hepatic nuclear RNA was isolated as described (9). RNA concentrations were determined spectrophotometrically at 260 nm, and assessed by agarose gel electrophoresis. Nuclear RNA (5 µg) was reverse-transcribed with random hexamers in a final volume of 20 µl using an RT-PCR kit (Invitrogen). PCR reactions were then performed with 0.5 µl of cDNA (11). Primer sequences are listed in Tables 1 and 2. The linear range of product amplification was established in pilot studies for each primer pair, and the cycle number that reflected the approximate midpoint was used in final experiments. This varied from 24 to 28 cycles. Results were quantified by densitometry after electrophoresis through 1.5% agarose gels. All experiments were performed on at least four separate occasions with comparable results.


View this table:
[in this window]
[in a new window]
  		TABLE 1
Primers used for PCR in ChIP assays

 


View this table:
[in this window]
[in a new window]
  		TABLE 2
Primers used for RT-PCR of nuclear RNA

 
Chromatin Immunoprecipitation Assays (ChIP)—Initial steps were modified from published protocols, as described (16, 18). For each time point a 200-mg fragment of rat liver was minced and incubated at 20 °C in 10 ml of Dulbecco's modified Eagle's medium plus 1% formaldehyde on a rotating platform for 15 min, followed by addition of 1.5 ml of 1 M glycine and incubation for an additional 5 min. After centrifugation at 200 x g for 5 min at 20 °C, the pellet was suspended in 1 ml of phosphate-buffered saline, transferred to a 2-ml Dounce, and homogenized with 10 strokes of a tight fitting pestle. After brief centrifugation in a microcentrifuge, the pellet was suspended in 400 µl of lysis buffer (50 mM Tris-HCl, 5 mM EDTA, 1% SDS pH 8.1 plus protease inhibitors), and incubated for 15 min at 4 °C. Each sample was sonicated at 4 °C using a total of 5 pulses for 15 s each of a Branson micro-tip sonicator at setting 5 interspersed with 30-s incubations on ice. After centrifugation at 14,000 x g for 10 min at 4 °C in a microcentrifuge, the supernatant was diluted to 4 ml with immunoprecipitation buffer (20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA pH 8.1 plus protease inhibitors), and 1-ml aliquots were used for immunoprecipitation (16, 18), with 3 µl of the Stat5 C17X antibody and 45 µl of a 50% slurry of protein A-agarose beads. DNA was extracted using the QiaQuick PCR DNA purification kit, following a protocol from the supplier, and was suspended in 50 µl of 10 mM Tris-HCl, 1 mM EDTA pH 8.0. PCR reactions were performed with 1 µl of DNA using the primer pairs listed in Table 1. The linear range of product amplification was established for each primer pair in pilot studies, and the cycle number that reflected the approximate midpoint was used in final experiments. This varied from 28 to 30 cycles. Results were visualized after electrophoresis through 1.5% agarose gels. All experiments were performed on at least three separate occasions with comparable results.


Figure 1
View larger version (5K):
[in this window]
[in a new window]
  		FIGURE 1.
Diagram of the rat IGF-I locus. A map of the IGF-I gene and flanking regions is depicted, illustrating promoters 1 and 2 (P1 and P2), and exons 1–6, with coding DNA shaded and non-coding white. The locations of the 5' distal region and HS7, two putative Stat5b binding segments, are indicated by arrows.

 

   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Identification of a Second GH-regulated Stat5 Binding Site within the Rat IGF-I Gene—In recent studies, we characterized a DNA segment within the second intron of the rat IGF-I gene that was able to confer GH responsiveness to the major IGF-I promoter in vitro, and that could bind Stat5b in vivo in a GH-dependent way (16). More recently, by a shotgun cloning approach, a different putative Stat5 binding element was mapped to the human IGF-I locus ~77 kb 5' to exon 1 (19). This DNA fragment when fused to reporter genes containing otherwise neutral promoters could confer responsiveness to constitutively active Stat5a or Stat5b. As this DNA sequence was conserved among several mammalian species (19), we sought to determine whether it was a cis-acting element in a GH-regulated IGF-I gene transcriptional pathway. As a first step, we asked whether this DNA element was a bona fide GH-activated Stat5b binding site in vivo. Shown in Fig. 1 is a map of the rat IGF-I locus, illustrating the six exons of the gene, its two promoters, P1 and P2, and the locations of HS7, our previously defined Stat5b binding site and GH response element (16), and the rat homologue of the 5' distal region identified in the human IGF-I locus (19).

We used ChIP experiments to determine if the 5' distal region was capable of binding Stat5b in vivo in a GH-dependent way. As seen in Fig. 2A, little Stat5b could be detected in hepatic chromatin from GH-deficient rats in association with any of the genes illustrated in the absence of hormone. Within 30 min of systemic GH injection, Stat5b was found at the IGF-I HS7 site, and binding persisted for the 60-min duration of the experiment. Identical kinetics of induction of Stat5b binding were observed on chromatin at the IGF-I 5' distal region, and at the promoters of two other known GH-activated and Stat5b-regulated genes, acid labile subunit (ALS) and Cis (20–22), while putative Stat sites in the Socs-3 promoter remained unoccupied by Stat5b, as did a region of the non-GH-regulated beta-actin gene, and intron 3 of the rat IGF-I gene.

GH-stimulated gene transcription was assessed in parallel with ChIP assays, using nuclear RNA isolated from the same livers to confirm that there were functional consequences of hormone treatment. The accumulation of nascent transcripts was measured by semi-quantitative RT-PCR assay. As pictured in Fig. 2B, transcription directed by the IGF-I promoters was stimulated within 30 min of systemic GH treatment and remained enhanced at 60 min. A similar rate and extent of activation was seen for ALS, Cis, and Socs-3 genes, while beta-actin gene expression remained constant. Thus, in vivo GH treatment rapidly stimulates binding of Stat5b to at least two sites within the IGF-I locus, coincident with potent stimulation of IGF-I gene transcription.

Response Element 1 of the 5' Distal Region Can Mediate GH-activated and Stat5b-dependent Gene Transcription—The 5' distal region of the rat IGF-I locus contains two potential Stat5 binding sites, here termed RE-1 and RE-2, that are separated by 228 nt of intervening DNA. We evaluated the transcriptional properties of the 5' distal region and RE-1 and RE-2 by performing reconstitution experiments in COS-7 cells with luciferase reporter genes containing IGF-I P1 without or with either a 352-nt segment of the 5' distal region or 825 nt HS7. Cells were transiently co-transfected with expression plasmids for the mouse GH receptor and wild-type rat Stat5b, and individual luciferase reporter genes. As seen in Fig. 3, GH treatment had no effect on IGF P1 as shown previously (16), stimulated a 4-fold increase in gene expression of IGF P1 plus HS7, and ~2-fold rise in reporter activity of IGF P1 when the 5' distal region was present.


Figure 2
View larger version (41K):
[in this window]
[in a new window]
  		FIGURE 2.
GH stimulates binding of Stat5b to the 5' distal region of the rat IGF-I gene coincident with activating IGF-I gene transcription. A, results of ChIP assays using an antibody to Stat5b and livers from pituitary-deficient male rats injected with recombinant rat GH for the times indicated. The locations of oligonucleotide primers used for each gene are displayed on the maps to the left. Sequences for all primers may be found in Table 1. B, time course of accumulation of nascent nuclear transcripts for IGF-I, ALS, Socs-3, Cis, and beta-actin genes after GH treatment, as measured by semi-quantitative RT-PCR using the oligonucleotide primers depicted in the maps to the left. DNA sequences for all primers may be found in Table 2. No transcripts were observed in the absence of the reverse transcription step, indicating no contamination with chromosomal DNA. Results for both A and B are representative of three to four independent experiments.

 


Figure 3
View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 3.
The distal 5' region of the IGF-I locus mediates GH-stimulated and Stat5b-regulated transcription of rat IGF-I promoter 1. Results of luciferase assays in COS-7 cells transiently transfected with expression plasmids encoding the mouse GH receptor and rat Stat5b and incubated with rat GH (40 nM)(dark bars) or vehicle (light bars) for 18 h. Each luciferase reporter gene contained 1711 bp of rat IGF-I promoter 1 and 328 bp of rat IGF-I exon 1 (IGFI P1). HS7 consists of an 825 bp segment of rat IGF-I intron 2, and was cloned 5' to IGF-I P1, as described (16). A 352-bp segment from the 5' distal region also was cloned 5' to IGF-I P1. The graph summarizes results of four independent experiments (mean ± S.E.), each performed in duplicate (*, p < 0.02 versus vehicle). Luciferase values for IGF-I P1 ranged from 2600 to 4900 relative light units/10 s.

 
To extend this observation of GH-stimulated gene transcription via the 5' distal region of the IGF-I locus, additional experiments were performed with luciferase reporter genes containing a minimal thymidine kinase promoter. As pictured in Fig. 4, in the presence of HS7, GH and Stat5b induced a nearly 8-fold increase in gene transcription, whereas with a fusion gene containing the 5' distal region, GH and Stat5b stimulated a ~3-fold rise in luciferase activity. The importance of the two REs for hormonal regulation was next examined after engineering point mutations into each site that would potentially eliminate binding of Stat5b. As also shown in Fig. 4, a ~3-fold increase in gene expression by GH and Stat5b was maintained when RE-2 was modified but the hormonal response declined to nearly background levels when either RE-1 or both sites were mutated. Thus, based on these results, HS7 appears to be a more potent GH response element than the 5' distal region, potentially because in HS7 both Stat5b binding sites are needed for full transcriptional activity (16), while in the 5' region, only RE-1 appears necessary for GH-induced gene transcription in the presence of Stat5b.


Figure 4
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 4.
RE-1 of the distal 5' region mediates GH-stimulated, Stat5b-dependent gene transcription. Results of luciferase assays in COS-7 cells transiently transfected with expression plasmids for the mouse GH receptor and rat Stat5b and incubated with rat GH (40 nM)(dark bars) or vehicle (light bars) for 18 h. Luciferase reporter genes contained the minimal TK promoter, with addition of either an 84-bp sequence spanning GHRE-1 and GHRE-2 of HS7, or a 352-bp segment from the distal 5'-region containing either wild-type or mutant versions of putative Stat5b sites 1 or 2 (open circles). Each mutant DNA sequence is indicated by an X (for site 1, TTCTAAGAA was changed to GTCTAAGTA, and for site 2, TTCTTAGAA was changed to GTCTTAGTA). The graph summarizes results of four independent experiments (mean ± S.E.), each performed in duplicate (* p < 0.02; ** p < 0.05 versus vehicle). Luciferase values for TK ranged from 11,000 to 49,000 relative light units/10 s.

 
DNA Binding Properties of RE-1 and RE-2—We used gel mobility shift experiments to determine if Stat5b could bind directly to RE-1 or RE-2 of the 5' distal region. Fig. 5 shows results using IR-labeled double-stranded oligonucleotides for each element, and nuclear protein extracts from COS-7 cells transfected with expression plasmids for the mouse GH receptor and either wild-type or constitutively-active rat Stat5b, and treated with GH or vehicle for 60 min. As depicted in the figure, GH induced binding of wild-type Stat5b to both DNA probes, with two discrete protein-DNA complexes being formed for each oligonucleotide. Binding of Stat5b to RE-1 appeared to be stronger than to RE-2, particularly to the complex showing faster mobility. Constitutively active Stat5b was able to bind to both oligonucleotides in the absence of hormone. Competition experiments using either homologous DNA or an unrelated sequence confirmed specific binding to each protein-DNA complex, whereas antibody supershift experiments showed that Stat5b interacted with each oligonucleotide.

We next evaluated binding of endogenous liver proteins to the putative REs in the 5' distal element in comparison to GHRE-1 and GHRE-2 of HS7. Illustrated in Fig. 6 are results of time course experiments using hepatic nuclear protein extracts from GH-deficient rats acutely treated with hormone. Inducible binding was observed with all four DNA probes beginning by 15 min after systemic GH injection, and reached a maximum by 30 to 60 min. Under the conditions used in these experiments, binding to RE-1 and GHRE-1 oligonucleotides was stronger than for RE-2 or GHRE-2, implying that the latter are lower affinity sites. A similar kinetic pattern of first one, and then three inducible protein-DNA complexes was observed for RE-1, RE-2, and GHRE-1 DNA, whereas only a single complex was seen for GHRE-2. As a control, gel mobility shift assays were performed with a double-stranded probe that recognizes members of the Sp1 family of transcription factors (23), which are not regulated by GH. As expected, protein-DNA binding was constant over the same time course, demonstrating that both the quantity and quality of nuclear protein extracts were comparable at each time point after hormone treatment.


Figure 5
View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 5.
Binding of Stat 5b to response elements 1 and 2 of the 5' distal region. Results of gel-mobility shift assays using IR-labeled double-stranded oligonucleotides for either RE-1 or RE-2 of the 5' distal region, and nuclear protein extracts from COS-7 cells transfected with expression plasmids encoding the mouse GH receptor and either wild-type (WT) or constitutively active (CA) N-terminal FLAG-tagged rat Stat5b. Cells transfected with Stat5bWT were incubated without serum for 4 h followed by addition of rat GH (40 nM) or vehicle for 60 min. Arrows delineate protein-DNA complexes, which are not observed in the absence of Stat5b (lanes 1). In cells transfected with Stat5bWT, protein-DNA binding is seen only after GH treatment (lanes 3 versus 2), whereas in cells expressing constitutively active Stat5b, binding is observed in the absence of hormone (lanes 4–8). Lanes 5 and 6 demonstrate specific protein-DNA binding as evidenced by competition with homologous oligonucleotides (lanes 5) but not DNA containing an Oct-1 recognition site (lanes 6). Lanes 7 show that an antibody to the FLAG epitope causes a supershift of each DNA-protein complex (arrowhead), whereas lanes 8 demonstrate that an irrelevant antibody to T7 does not. Unbound probe has been electrophoresed beyond the bottom of each gel.

 


Figure 6
View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 6.
In vivo GH treatment induces binding of rat hepatic nuclear proteins to response elements 1 and 2 of the 5' distal region and HS7 GHRE 1 and 2. Results of gel-mobility shift assays using IR-labeled double-stranded oligonucleotides for either RE-1 or RE-2 of the 5' distal region, GHRE-1 or GHRE-2 of HS7, or Sp1, and nuclear protein extracts (5 µg) from GH-deficient male rats after systemic GH treatment for 0, 15, 30, or 60 min. Arrows indicate protein-DNA complexes, and arrowheads unbound probe.

 
RE-1 Is a Very High Affinity Binding Site for Stat5b—The relative affinity for Stat5b of RE-1 of the 5' distal region was examined using COS-7 nuclear proteins isolated at 60 min after GH, and a variety of unlabeled competitor oligonucleotides. As shown in Fig. 7, unlabeled RE-1 competed avidly with itself, causing an 80% decline in both protein-DNA complexes at 5x excess molar concentration, whereas RE-2, GHRE-1, and GHRE-2 were only effective at 50x molar excess, and the unrelated binding site for Oct-1 was inert.

Quantitative gel-mobility shift assays were performed next to determine the affinity of Stat5b for both RE-1 of the 5'-region and GHRE-1 of HS7. Nuclear extracts from COS-7 cells expressing constitutively active Stat5b were used as the source of recombinant protein, and DNA-protein binding reactions were performed with a constant quantity of nuclear protein (2.8 µg) and a 50-fold concentration range of IR-labeled double-stranded oligonucleotides (0.5–25 nM, Fig. 8). For each probe, binding was saturable, with an EC50 of ~1 nM for RE-1 and ~4nM for GHRE-1 (compared with Figs. 5 and 7, where a doublet was seen, only a single protein-DNA complex was observed for RE-1 in Fig. 8 because electrophoresis was performed for a shorter time to visualize unbound probe DNA). The calculated Kd of 0.82 nM for GHRE-1 was very similar to values reported for the binding of Stat1 to a variety of high affinity sites (~1 nM, Ref. 24), whereas the Kd for 5' RE-1 of 0.02 nM was significantly higher. In contrast, using the same experimental approach we were unable to calculate the Kd of binding of Stat5b to either RE-2 or GHRE-2, indicating that they are lower affinity sites. Taken together, the results in Figs. 5, 6, 7, 8 show that RE-1 and RE-2 of the 5' distal region, and GHRE-1 and -2 of HS7 are bona fide Stat5b binding elements, and that the 5' distal region and HS7 each contain one higher affinity and one lower affinity Stat5b site.


Figure 7
View larger version (51K):
[in this window]
[in a new window]
  		FIGURE 7.
Cross-competition among rat IGF-I Stat5b sites. Gel mobility shift experiments were performed with IR-labeled double-stranded probe RE-1, nuclear protein extracts from COS-7 cells transfected with expression plasmids for the mouse GH receptor and wild-type N-terminal FLAG-tagged rat Stat5b, and treated with recombinant rat GH (40 nM) for 60 min, and unlabeled competitor DNAs at 5- and 50-fold molar excess. Arrows indicate protein-DNA complexes. Unbound probe has been electrophoresed beyond the bottom of each gel.

 


Figure 8
View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 8.
Assessing affinity of binding of Stat 5b to site 1 of the 5' distal region and HS7 GHRE 1. Quantitative gel-mobility shift experiments were performed as described under "Experimental Procedures" with varying concentrations of IR-labeled double-stranded oligonucleotides for RE-1 (A) or GHRE-1 (B), and 2.8 µg of nuclear protein from COS-7 cells transfected with an expression plasmids encoding constitutively active N-terminal FLAG-tagged rat Stat5b. DNA binding was quantified with a LiCoR Odyssey infrared scanner and v1.2 analysis software, and results were plotted as shown. Representative experiments are shown in the left panels, binding curves are illustrated in the center panels, and Scatchard plots are displayed in the right panels.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The GH-IGF-I pathway plays a central role in the control of postnatal somatic growth in humans and in nearly all other mammals (4–6). Despite considerable interest in this pathway with regard to human physiology and health, the biochemical mechanisms by which GH regulates IGF-I expression have proven to be difficult to unravel. Only recently has experimental evidence emerged demonstrating that Stat5b is a key intermediate in the steps between binding of GH to its cell membrane-spanning receptor and onset of IGF-I gene transcription in the nucleus (11). By a combination of approaches we previously identified and analyzed a DNA segment termed HS7 in the second intron of the rat IGF-I gene that contains tandem Stat5 binding sites, and showed that it functions as a cis-regulatory region capable of mediating GH-induced IGF-I gene transcription (16). Now we have characterized a second putative Stat5 binding segment in the rat IGF-I locus that maps 73 kb 5' of exon 1, and nearly 77 kb from HS7. We find that GH treatment also rapidly stimulated binding of Stat5b to chromatin at this 5' distal region coincident with the onset of IGF-I gene transcription in vivo, and demonstrate that similar to HS7 this DNA segment conferred responsiveness to the major IGF-I promoter and to a neutral promoter in cell-based reconstitution experiments. Like HS7, the 5' distal region appears to contain tandem Stat5 binding sites with widely different affinities for Stat5b, but unlike HS7, only one of the two sites appears essential for GH- and Stat5b-regulated gene expression, an observation that may account for the weaker actions of the 5' distal region as a transcriptional enhancer in cell-based reconstitution assays. In aggregate, these results begin to elucidate the complex molecular architecture of the signal transduction pathway responsible for GH-activated IGF-I gene transcription.

The biological effects of GH are multifactorial and include early activation of target genes that are regulated by distinct signaling steps involving both pre-existing and newly synthesized intermediates (2). Stats are latent transcription factors that are present in the cytoplasm in advance of hormonal stimulation (25). Previous studies have demonstrated that GH can rapidly activate Stats 1, 3, 5a, and 5b both in vivo and in cell culture by stimulating their tyrosine phosphorylation, dimerization, and nuclear translocation (7), and have supported the idea that together these proteins mediate a substantial fraction of the transcriptional effects of GH (26). In addition to now showing that Stat5b binds to DNA in chromatin within at least two distinct regions in the IGF-I locus, we demonstrate that the promoters for both ALS and Cis contain bona fide Stat5b binding sites that become occupied in chromatin in a GH-dependent way coincident with their gene activation. In contrast, although Socs-3 is also a GH-inducible gene (11, 27–30), similar sequences within its proximal promoter did not bind Stat5b in vivo, results consistent with previous observations showing that these sites are dispensable for hormone-stimulated transcription in cell-based promoter-reporter assays (27). Thus, through the combination of ChIP experiments with hepatic chromatin and measurements of GH-stimulated in vivo transcription, we are able to discriminate between true and false GH-regulated Stat5b response elements.

Stat proteins typically bind as dimers to specific sites on DNA, which optimally consist of the nucleotide sequence 5'-TTCNnGAA-3', where N is any deoxyribonucleotide and n ranges from 2–4 (31). Through use of an iterative DNA binding assay, both Soldaini et al. (32) and Ehret et al. (33) have shown for Stat5 that n = 3, which is the same spacing observed in the paired Stat5 sites found in both the 5' distal region and in HS7. Soldaini et al. additionally attempted to discriminate between optimal DNA sequences for Stat5a and Stat5b, proteins that are 91% identical overall and 97% identical in their nucleotide binding domains (34). Not surprisingly, the core binding sequences could not be distinguished from each other, although Stat5a was shown to bind not only as a dimer to this core element but also as a tetramer to DNA sequences that contained two less than optimal cores in tandem (32). In contrast, in the same assays Stat5b only recognized optimal core sequences and only bound to DNA as a dimer (32). Other studies addressing binding of Stat5 to the human Cis promoter also have concluded that Stat5a can form tetramers on DNA, while Stat5b cannot (22). Given these published observations, it seems unlikely that either of the two discrete protein-DNA complexes seen with RE-1 and with RE-2 probes in Figs. 5 and 7 represent Stat5b tetramers, although as supported by results of antibody super-shift experiments, both bands contain Stat5b. Additional studies will be needed to identify all of the proteins present in each complex. Similarly, the nature of the complexes formed with hepatic nuclear proteins will need to be characterized.

RE-1 of the 5' distal region is identical in its core Stat5 binding sequence to a site in the proximal HNF-6 promoter that is responsible for gene activation by GH (35), whereas RE-2 matches both a site in the prolactin-induced {alpha}s1 casein promoter (36) and GHRE-2 of HS7 (16). Along with results of gel-mobility shift experiments presented in Figs. 5 and 6, these observations suggest that both RE-1 and RE-2 of the 5' distal region are bona fide Stat5b sites. Yet, our studies to address functional effects of RE-1 and RE-2, which are separated by 228 nucleotides in the linear DNA sequence, have indicated that only RE-1 is active, at least as assessed by promoter-reporter gene experiments. As these latter studies did not examine binding of Stat5b in chromatin, it remains a formal possibility that cooperative interactions do take place between the RE-1 and RE-2 sites, as long as RE-1 retains high affinity binding of Stat5b.

The identification of two widely spaced potential Stat5b-binding GH response elements in the IGF-I locus raises several questions regarding mechanisms of GH-stimulated IGF-I gene transcription. First, do both regions contribute to hormone-regulated IGF-I gene expression? We do not know if either HS7 or the 5' distal region becomes physically associated with the two IGF-I promoters just prior to onset of GH-stimulated IGF-I gene transcription. The interaction of a distant enhancer with its cognate promoter has been characterized for several other genes recently (37–40), leading to the idea of inducible looping of DNA in chromatin as part of the process of gene activation. This remains to be tested for the putative enhancers in the IGF-I locus. Second, what coactivators interact with Stat5b to mediate GH-stimulated IGF-I gene transcription? At present, we know little about the assembly of transcriptional cofactors at either site, although in preliminary studies we find that acetylation of core histones accompanies GH-induced binding of Stat5b to HS7 (data not shown). CBP, p300 (41), SRC-1 (42), Nmi (43), and the glucocorticoid receptor (44, 45) are among several characterized Stat5-binding proteins, yet none have been demonstrated to physically interact with the IGF-I locus on chromatin, or to play a role in GH-stimulated IGF-I gene transcription. Third, do additional GH response elements exist in the IGF-I gene? Both HS7 and the 5' distal region were initially identified by functional studies. HS7 was shown to undergo a reversible alteration in chromatin structure upon systemic GH treatment (9), while the 5' distal region was characterized by a shotgun cloning strategy as a chromosomal segment that conferred responsiveness to constitutively active Stat5a in promoter-reporter gene assays (19). Evaluation of the nucleotide sequences of the human, rat, and mouse IGF-I loci reveals the presence of over 90 potential single Stat5 consensus sites within the 200 kb including each gene and flanking DNA, with more than a dozen paired sites in each species (data not shown). Although several other potential single and paired sites demonstrate conservation across species, except for HS7 and the 5' distal region, none have been examined for GH-stimulated binding of Stat5 in chromatin or in vitro, and none have been tested in functional studies.

GH and IGF-I are critical for normal somatic growth during childhood and play key roles in tissue repair and regeneration in the adult (2–5, 46, 47). By contrast, there is a dark side to this pathway with implications for increased cancer risk and progression (48), and for enhanced tissue senescence and aging (49–51). Any future potential therapeutic interventions to maximize the safe use of these potent agents will require a detailed understanding of the biochemical and molecular basis of their actions.


   FOOTNOTES
 
* These studies were supported in part by National Institutes of Health Grants F32 DK070447 (to D. J. C.), R01 DK063073 (to P. R.), and R01 DK67961 (to H. J.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, OR Health & Science University, 3181 SW Sam Jackson Road, Portland, OR 97239, Mail code L224. Tel.: 503-494-0536; Fax: 503-494-8393; E-mail: rotweinp{at}ohsu.edu.

2 The abbreviations used are: GH, growth hormone; ChIP, chromatin immunoprecipitation assay; IGF, insulin-like growth factor; TK, thymidine kinase; Stat, signal transducer and activator of transcription; RT, reverse transcriptase; ALS, acid labile subunit; RE, response element. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Salmon, W. D., and Daughaday, W. H. (1957) J. Lab. Clin. Med. 49, 825–836[Medline] [Order article via Infotrieve]
  2. Herrington, J., and Carter-Su, C. (2001) Trends Endocrinol. Metab. 12, 252–257[CrossRef][Medline] [Order article via Infotrieve]
  3. Jones, J. I., and Clemmons, D. R. (1995) Endocr. Rev. 16, 3–34[Abstract/Free Full Text]
  4. Schoenle, E., Zapf, J., Humbel, R. E., and Froesch, E. R. (1982) Nature 296, 252–253[CrossRef][Medline] [Order article via Infotrieve]
  5. Guler, H. P., Zapf, J., Scheiwiller, E., and Froesch, E. R. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4889–4893[Abstract/Free Full Text]
  6. Le Roith, D., Bondy, C., Yakar, S., Liu, J. L., and Butler, A. (2001) Endocr. Rev. 22, 53–74[Abstract/Free Full Text]
  7. Rotwein, P., Thomas, M. J., Harris, D. M., Gronowski, A. M., and LeStunff, C. (1997) J. Anim. Sci. 75, 11–19[Abstract/Free Full Text]
  8. Woelfle, J., and Rotwein, P. (2004) Am. J. Physiol. Endocrinol. Metab. 286, E393–401[Abstract/Free Full Text]
  9. Bichell, D. P., Kikuchi, K., and Rotwein, P. (1992) Mol. Endocrinol. 6, 1899–1908[Abstract/Free Full Text]
  10. D'Ercole, A. J., Stiles, A. D., and Underwood, L. E. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 935–939[Abstract/Free Full Text]
  11. Woelfle, J., Billiard, J., and Rotwein, P. (2003) J. Biol. Chem. 278, 22696–22702[Abstract/Free Full Text]
  12. Rotwein, P. (1999) in The IGF System (Rosenfeld, R., and Roberts, C. J., eds) pp. 19–35, Humana Press, Totowa, NJ
  13. Udy, G. B., Towers, R. P., Snell, R. G., Wilkins, R. J., Park, S. H., Ram, P. A., Waxman, D. J., and Davey, H. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7239–7244[Abstract/Free Full Text]
  14. Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G., and Ihle, J. N. (1998) Cell 93, 841–850[CrossRef][Medline] [Order article via Infotrieve]
  15. Kofoed, E. M., Hwa, V., Little, B., Woods, K. A., Buckway, C. K., Tsubaki, J., Pratt, K. L., Bezrodnik, L., Jasper, H., Tepper, A., Heinrich, J. J., and Rosenfeld, R. G. (2003) N. Engl. J. Med. 349, 1139–1147[Free Full Text]
  16. Woelfle, J., Chia, D. J., and Rotwein, P. (2003) J. Biol. Chem. 278, 51261–51266[Abstract/Free Full Text]
  17. Gronowski, A. M., and Rotwein, P. (1994) J. Biol. Chem. 269, 7874–7878[Abstract/Free Full Text]
  18. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., and Brown, M. (2000) Cell 103, 843–852[CrossRef][Medline] [Order article via Infotrieve]
  19. Wang, Y., and Jiang, H. (2005) J. Biol. Chem. 280, 10955–10963[Abstract/Free Full Text]
  20. Ooi, G. T., Cohen, F. J., Tseng, L. Y., Rechler, M. M., and Boisclair, Y. R. (1997) Mol. Endocrinol. 11, 997–1007[Abstract/Free Full Text]
  21. Ooi, G. T., Hurst, K. R., Poy, M. N., Rechler, M. M., and Boisclair, Y. R. (1998) Mol. Endocrinol. 12, 675–687[Abstract/Free Full Text]
  22. Verdier, F., Rabionet, R., Gouilleux, F., Beisenherz-Huss, C., Varlet, P., Muller, O., Mayeux, P., Lacombe, C., Gisselbrecht, S., and Chretien, S. (1998) Mol. Cell. Biol. 18, 5852–5860[Abstract/Free Full Text]
  23. Boulikas, T. (1994) Crit. Rev. Eukaryot. Gene Expr. 4, 117–321[Medline] [Order article via Infotrieve]
  24. Vinkemeier, U., Cohen, S. L., Moarefi, I., Chait, B. T., Kuriyan, J., and Darnell, J. E. J. (1996) EMBO J. 15, 5616–5626[Medline] [Order article via Infotrieve]
  25. Levy, D. E., and Darnell, J. E. J. (2002) Nat. Rev. Mol. Cell. Biol. 3, 651–662[CrossRef][Medline] [Order article via Infotrieve]
  26. Herrington, J., Smit, L. S., Schwartz, J., and Carter-Su, C. (2000) Oncogene 19, 2585–2597[CrossRef][Medline] [Order article via Infotrieve]
  27. Paul, C., Seiliez, I., Thissen, J. P., and Le Cam, A. (2000) Eur. J. Biochem. 267, 5849–5857[Medline] [Order article via Infotrieve]
  28. Adams, T. E., Hansen, J. A., Starr, R., Nicola, N. A., Hilton, D. J., and Billestrup, N. (1998) J. Biol. Chem. 273, 1285–1287[Abstract/Free Full Text]
  29. Davey, H. W., McLachlan, M. J., Wilkins, R. J., Hilton, D. J., and Adams, T. E. (1999) Mol. Cell. Endocrinol. 158, 111–116[CrossRef][Medline] [Order article via Infotrieve]
  30. Tollet-Egnell, P., Flores-Morales, A., Stavreus-Evers, A., Sahlin, L., and Norstedt, G. (1999) Endocrinology 140, 3693–3704[Abstract/Free Full Text]
  31. Horvath, C. M. (2000) Trends Biochem. Sci. 25, 496–502[CrossRef][Medline] [Order article via Infotrieve]
  32. Soldaini, E., John, S., Moro, S., Bollenbacher, J., Schindler, U., and Leonard, W. J. (2000) Mol. Cell. Biol. 20, 389–401[Abstract/Free Full Text]
  33. Ehret, G. B., Reichenbach, P., Schindler, U., Horvath, C. M., Fritz, S., Nabholz, M., and Bucher, P. (2001) J. Biol. Chem. 276, 6675–6688[Abstract/Free Full Text]
  34. Liu, X., Robinson, G. W., Gouilleux, F., Groner, B., and Hennighausen, L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8831–8835[Abstract/Free Full Text]
  35. Lahuna, O., Rastegar, M., Maiter, D., Thissen, J. P., Lemaigre, F. P., and Rousseau, G. G. (2000) Mol. Endocrinol. 14, 285–294[Abstract/Free Full Text]
  36. Jolivet, G., L'Hotte, C., Pierre, S., Tourkine, N., and Houdebine, L. M. (1996) FEBS Lett. 389, 257–262[CrossRef][Medline] [Order article via Infotrieve]
  37. Nobrega, M. A., Ovcharenko, I., Afzal, V., and Rubin, E. M. (2003) Science 302, 413[Free Full Text]
  38. Jarman, A. P., Wood, W. G., Sharpe, J. A., Gourdon, G., Ayyub, H., and Higgs, D. R. (1991) Mol. Cell. Biol. 11, 4679–4689[Abstract/Free Full Text]
  39. Carter, D., Chakalova, L., Osborne, C. S., Dai, Y. F., and Fraser, P. (2002) Nat. Genet. 32, 623–626[CrossRef][Medline] [Order article via Infotrieve]
  40. Murrell, A., Heeson, S., and Reik, W. (2004) Nat. Genet. 36, 889–893[CrossRef][Medline] [Order article via Infotrieve]
  41. Pfitzner, E., Jahne, R., Wissler, M., Stoecklin, E., and Groner, B. (1998) Mol. Endocrinol. 12, 1582–1593[Abstract/Free Full Text]
  42. Litterst, C. M., Kliem, S., Marilley, D., and Pfitzner, E. (2003) J. Biol. Chem. 278, 45340–45351[Abstract/Free Full Text]
  43. Zhu, M., John, S., Berg, M., and Leonard, W. J. (1999) Cell 96, 121–130[CrossRef][Medline] [Order article via Infotrieve]
  44. Cella, N., Groner, B., and Hynes, N. E. (1998) Mol. Cell. Biol. 18, 1783–1792[Abstract/Free Full Text]
  45. Bergad, P. L., Towle, H. C., and Berry, S. A. (2000) J. Biol. Chem. 275, 8114–8120[Abstract/Free Full Text]
  46. Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V., and Efstratiadis, A. (2001) Dev. Biol. 229, 141–162[CrossRef][Medline] [Order article via Infotrieve]
  47. Daughaday, W. H., and Rotwein, P. (1989) Endocr. Rev. 10, 68–91[Abstract/Free Full Text]
  48. Pollak, M. (2000) Growth Horm. IGF Res. 10, Suppl. A, S6–S7[Medline] [Order article via Infotrieve]
  49. Bartke, A. (2005) Endocrinology 146, 3718–3723[Abstract/Free Full Text]
  50. Katic, M., and Kahn, C. R. (2005) Cell Mol. Life Sci. 62, 320–343[CrossRef][Medline] [Order article via Infotrieve]
  51. Tatar, M., Bartke, A., and Antebi, A. (2003) Science 299, 1346–1351[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
L. Moller, L. Dalman, H. Norrelund, N. Billestrup, J. Frystyk, N. Moller, and J. O. L. Jorgensen
Impact of Fasting on Growth Hormone Signaling and Action in Muscle and Fat
J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 965 - 972.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. D. Buzzelli, M. Nagarajan, J. F. Radtka, M. L. Shumate, M. Navaratnarajah, C. H. Lang, and R. N. Cooney
Nuclear Factor-{kappa}B Mediates the Inhibitory Effects of Tumor Necrosis Factor-{alpha} on Growth Hormone-Inducible Gene Expression in Liver
Endocrinology, December 1, 2008; 149(12): 6378 - 6388.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B.-M. Zhu, S. K. McLaughlin, R. Na, J. Liu, Y. Cui, C. Martin, A. Kimura, G. W. Robinson, N. C. Andrews, and L. Hennighausen
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression
Blood, September 1, 2008; 112(5): 2071 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
V. Wauthier and D. J. Waxman
Sex-Specific Early Growth Hormone Response Genes in Rat Liver
Mol. Endocrinol., August 1, 2008; 22(8): 1962 - 1974.
[Abstract] [Full Text] [PDF]

Home page
 J DAIRY SCIHome page
M. L. Rhoads, J. P. Meyer, S. J. Kolath, W. R. Lamberson, and M. C. Lucy
Growth Hormone Receptor, Insulin-Like Growth Factor (IGF)-1, and IGF-Binding Protein-2 Expression in the Reproductive Tissues of Early Postpartum Dairy Cows
J Dairy Sci, May 1, 2008; 91(5): 1802 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Eleswarapu, Z. Gu, and H. Jiang
Growth Hormone Regulation of Insulin-Like Growth Factor-I Gene Expression May Be Mediated by Multiple Distal Signal Transducer and Activator of Transcription 5 Binding Sites
Endocrinology, May 1, 2008; 149(5): 2230 - 2240.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. N. Dhir, C. Thangavel, and B. H. Shapiro
Attenuated Expression of Episodic Growth Hormone-Induced CYP2C11 in Female Rats Associated with Suboptimal Activation of the Jak2/Stat5B and Other Modulating Signaling Pathways
Drug Metab. Dispos., November 1, 2007; 35(11): 2102 - 2110.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Jiang, Y. Wang, M. Wu, Z. Gu, S. J. Frank, and R. Torres-Diaz
Growth Hormone Stimulates Hepatic Expression of Bovine Growth Hormone Receptor Messenger Ribonucleic Acid through Signal Transducer and Activator of Transcription 5 Activation of a Major Growth Hormone Receptor Gene Promoter
Endocrinology, July 1, 2007; 148(7): 3307 - 3315.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Ono, D. J. Chia, R. Merino-Martinez, A. Flores-Morales, T. G. Unterman, and P. Rotwein
Signal Transducer and Activator of Transcription (Stat) 5b-Mediated Inhibition of Insulin-Like Growth Factor Binding Protein-1 Gene Transcription: A Mechanism for Repression of Gene Expression by Growth Hormone
Mol. Endocrinol., June 1, 2007; 21(6): 1443 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. G. Holloway, Y. Cui, E. V. Laz, A. Hosui, L. Hennighausen, and D. J. Waxman
Loss of Sexually Dimorphic Liver Gene Expression upon Hepatocyte-Specific Deletion of Stat5a-Stat5b Locus
Endocrinology, May 1, 2007; 148(5): 1977 - 1986.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
C. M. Alfieri, H. J. Evans-Anderson, and K. E. Yutzey
Developmental regulation of the mouse IGF-I exon 1 promoter region by calcineurin activation of NFAT in skeletal muscle
Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1887 - C1894.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. J. Frank
Growth Hormone, Insulin-Like Growth Factor I, and Growth: Local Knowledge
Endocrinology, April 1, 2007; 148(4): 1486 - 1488.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Z. E. Floyd, B. M. Segura, F. He, and J. M. Stephens
Degradation of STAT5 proteins in 3T3-L1 adipocytes is induced by TNF-{alpha} and cycloheximide in a manner independent of STAT5A activation
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E461 - E468.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
O. M. Vidal, R. Merino, E. Rico-Bautista, L. Fernandez-Perez, D. J. Chia, J. Woelfle, M. Ono, B. Lenhard, G. Norstedt, P. Rotwein, et al.
In Vivo Transcript Profiling and Phylogenetic Analysis Identifies Suppressor of Cytokine Signaling 2 as a Direct Signal Transducer and Activator of Transcription 5b Target in Liver
Mol. Endocrinol., January 1, 2007; 21(1): 293 - 311.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J. W Kim, R. P Rhoads, N. Segoale, N. B Kristensen, D. E Bauman, and Y. R Boisclair
Isolation of the cDNA encoding the acid labile subunit (ALS) of the 150 kDa IGF-binding protein complex in cattle and ALS regulation during the transition from pregnancy to lactation.
J. Endocrinol., June 1, 2006; 189(3): 583 - 593.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/6/3190    most recent
M510204200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chia, D. J.
Right arrow Articles by Rotwein, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chia, D. J.
Right arrow Articles by Rotwein, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement